130 related articles for article (PubMed ID: 15879353)
41. Radiation therapy in the treatment of pituitary tumors.
Ghostine S; Ghostine MS; Johnson WD
Neurosurg Focus; 2008; 24(5):E8. PubMed ID: 18447747
[TBL] [Abstract][Full Text] [Related]
42. [Treatment of acromegaly in Aarhus University Hospital. A retrospective investigation of the period from 1994 to 2004].
Madsen M; Matthiesen EB; Poulsen PL; Weeke J; Astrup J; Jørgensen JO
Ugeskr Laeger; 2007 Mar; 169(10):907-10. PubMed ID: 17359734
[TBL] [Abstract][Full Text] [Related]
43. The expression of E-cadherin in somatotroph pituitary adenomas is related to tumor size, invasiveness, and somatostatin analog response.
Fougner SL; Lekva T; Borota OC; Hald JK; Bollerslev J; Berg JP
J Clin Endocrinol Metab; 2010 May; 95(5):2334-42. PubMed ID: 20335450
[TBL] [Abstract][Full Text] [Related]
44. Acromegaly and its treatment.
Lamberts SW
J Endocrinol; 1997 Oct; 155 Suppl 1():S49-51; discussion S67-71. PubMed ID: 9389995
[No Abstract] [Full Text] [Related]
45. The therapeutic value of somatostatin and its analogues.
Farooqi S; Bevan JS; Sheppard MC; Wass JA
Pituitary; 1999 Jun; 2(1):79-88. PubMed ID: 11081176
[TBL] [Abstract][Full Text] [Related]
46. A new treatment for an old disease.
Daughaday WH
N Engl J Med; 1985 Dec; 313(25):1604-5. PubMed ID: 2866446
[No Abstract] [Full Text] [Related]
47. Primary Medical Treatment of Thyrotropin-Secreting Pituitary Adenomas by First-Generation Somatostatin Analogs: A Case Study of Seven Patients.
Rimareix F; Grunenwald S; Vezzosi D; Rivière LD; Bennet A; Caron P
Thyroid; 2015 Aug; 25(8):877-82. PubMed ID: 26244412
[TBL] [Abstract][Full Text] [Related]
48. Acromegaly can be cured by first-line pasireotide treatment?
Chiloiro S; Giampietro A; Bianchi A; Tartaglione T; Bima C; Vita MG; Spinello M; Pontecorvi A; De Marinis L
Endocrine; 2019 Apr; 64(1):196-199. PubMed ID: 30798431
[No Abstract] [Full Text] [Related]
49. First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group.
Colao A; Martino E; Cappabianca P; Cozzi R; Scanarini M; Ghigo E;
J Endocrinol Invest; 2006 Dec; 29(11):1017-20. PubMed ID: 17259801
[No Abstract] [Full Text] [Related]
50. [Management of acromegaly in 2003].
Bertherat J; Bouchard P; Chanson P; Benoît A; Bourgeon M; Brémont C; Kahal Z; Mathé C; Requeda E
Ann Endocrinol (Paris); 2003 Apr; 64(2):I-IV. PubMed ID: 12773933
[No Abstract] [Full Text] [Related]
51. Comparison of the effects of primary somatostatin analogue therapy and pituitary adenomectomy on survival in patients with acromegaly: a retrospective cohort study.
Bogazzi F; Colao A; Rossi G; Lombardi M; Urbani C; Sardella C; Iannelli A; Scattina I; Manetti L; Del Sarto S; Pivonello R; Grasso LF; Lupi I; Auriemma RS; Lombardi G; Martino E
Eur J Endocrinol; 2013 Sep; 169(3):367-76. PubMed ID: 23828855
[TBL] [Abstract][Full Text] [Related]
52. The treatment of acromegaly.
Lamberts SW; Klijn JG; De Lange SA; Birkenhäger JC
Neth J Med; 1979; 22(5):161-6. PubMed ID: 388245
[No Abstract] [Full Text] [Related]
53. Transsphenoidal adenomectomy for growth hormone-secreting pituitary adenomas in acromegaly: outcome analysis and determinants of failure.
Tindall GT; Oyesiku NM; Watts NB; Clark RV; Christy JH; Adams DA
J Neurosurg; 1993 Feb; 78(2):205-15. PubMed ID: 8421204
[TBL] [Abstract][Full Text] [Related]
54. [Acromegaly; diagnosis and treatment].
van der Lely AJ; de Herder WW; Hofland LJ; Lamberts SW
Ned Tijdschr Geneeskd; 1996 Jul; 140(28):1436-40. PubMed ID: 8766766
[No Abstract] [Full Text] [Related]
55. Pre-surgical treatment with somatostatin analogues in patients with acromegaly: the case for.
Ferone D; Gatto F; Minuto F
J Endocrinol Invest; 2012 Jun; 35(6):613-5. PubMed ID: 22776973
[No Abstract] [Full Text] [Related]
56. Effect of somatostatin on repair of ionizing radiation-induced DNA damage in pituitary adenoma cells GH3.
Řezáčová M; Čáp J; Vokurková D; Lukášová E; Vávrová J; Cerman J; Mašín V; Mazánková N
Physiol Res; 2008; 57(2):225-235. PubMed ID: 17552875
[TBL] [Abstract][Full Text] [Related]
57. Evolution of (18)FDG pituitary uptake after medical control of acromegaly.
Maiza JC; Revel C
Pituitary; 2014 Jun; 17(3):296-7. PubMed ID: 23982451
[No Abstract] [Full Text] [Related]
58. Pasireotide in acromegaly by aggressive tumors, description of four clinical cases. Towards a personalized medicine.
Biagetti B; Obiols G; Martinez Saez E; Cordero E; Mesa J
Endocrinol Diabetes Nutr (Engl Ed); 2018 Feb; 65(2):130-132. PubMed ID: 29371000
[No Abstract] [Full Text] [Related]
59. Acromegaly: selection parameters and operative results.
Weiss MH
Clin Neurosurg; 1980; 27():31-7. PubMed ID: 7273559
[No Abstract] [Full Text] [Related]
60. Non-surgical Interventions for Pituitary Lesions.
Suda N
Otolaryngol Clin North Am; 2022 Apr; 55(2):287-304. PubMed ID: 35256178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
